Trends in family planning and counselling for women with sickle cell disease in the UK over two decades

Journal of Family Planning and Reproductive Health Care

Volumn 41, Issue 2, 2015, Pages 96-101

  Eissa, Asma A ^a   Tuck, Susan M ^a   Rantell, Khadija ^b   Stott, Daniel ^c  

^a ROYAL FREE HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DESOGESTREL; DROSPIRENONE; GESTAGEN; LEVONORGESTREL; MEDROXYPROGESTERONE ACETATE; NORETHISTERONE; NORETHISTERONE ACETATE; ORAL CONTRACEPTIVE AGENT; CONTRACEPTIVE AGENT;

ADULT; AGED; AMENORRHEA; ARTICLE; CEREBROVASCULAR ACCIDENT; CONTRACEPTION; CONTRACEPTIVE BEHAVIOR; COPPER INTRAUTERINE DEVICE; CROSS-SECTIONAL STUDY; ETONORGESTREL SUBCUTANEOUS IMPLANT; FAMILY PLANNING; FEMALE; FEMALE CONTRACEPTIVE DEVICE; HEALTH SURVEY; HUMAN; INTERVIEW; INTRAUTERINE CONTRACEPTIVE DEVICE; LEVONORGESTREL RELEASING INTRAUTERINE SYSTEM; MAJOR CLINICAL STUDY; MEDICAL HISTORY; MENSTRUAL IRREGULARITY; MENSTRUATION; MULTICENTER STUDY; PATIENT COUNSELING; PATIENT EDUCATION; PREGNANCY; PREGNANT WOMAN; SICKLE CELL ANEMIA; UNITED KINGDOM; UNPLANNED PREGNANCY; ADOLESCENT; ANEMIA, SICKLE CELL; COUNSELING; DRUG EFFECTS; ENGLAND; MIDDLE AGED; PROCEDURES; QUESTIONNAIRE; STATISTICS AND NUMERICAL DATA; TRENDS;

ADOLESCENT; ADULT; AGED; ANEMIA, SICKLE CELL; CONTRACEPTION BEHAVIOR; CONTRACEPTIVE AGENTS, FEMALE; COUNSELING; CROSS-SECTIONAL STUDIES; FAMILY PLANNING SERVICES; FEMALE; HUMANS; INTRAUTERINE DEVICES, MEDICATED; LEVONORGESTREL; LONDON; MIDDLE AGED; PREGNANCY; PREGNANCY, UNPLANNED; SURVEYS AND QUESTIONNAIRES;

EID: 84925325686     PISSN: 14711893     EISSN: None     Source Type: Journal    
DOI: 10.1136/jfprhc-2013-100763     Document Type: Article

References (26)

1. Streetly A, Maxwell K, Campbell B. Coordinated neonatal screening programme for haemoglobin disorders is needed. BMJ 1998;316:937.
2. Charache S, Niebyl JR. Pregnancy in sickle cell disease. Clin Haematol 1985;14:729-746.
3. Tuck SM, Studd JW, White JM. Pregnancy in sickle cell disease in the UK. Br J Obstet Gynaecol 1983;90:112-117.
4. Howard RJ, Tuck SM, Pearson TC. Pregnancy in sickle cell disease in the UK: results of a multicentre survey of the effect of prophylactic blood transfusion on maternal and fetal outcome. Br J Obstet Gynaecol 1995;102:947-951.
5. Serjeant GR, Loy LL, Crowther M, et al. Outcome of pregnancy in homozygous sickle cell disease. Obstet Gynecol 2004;103:1278-1285.
6. Wilkinson H. Saving mothers' lives. Reviewing maternal deaths to make motherhood safer: 2006-2008. BJOG 2011;118:1402-1404.
7. Haddad LB, Curtis KM, Legardy-Williams JK, et al. Contraception for individuals with sickle cell disease: a systematic review of the literature. Contraception 2012;85:527-537.
8. Cramer D, Poulter NR, Farley TMM, et al. Safety of combined oral contraceptive pills. Lancet 1996;347:546-549.
9. Jick H, Jick SS, Gurewich V, et al. Risk of idiopathic cardiovascular death and non-fatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet 1995;346:1589-1593.
10. Helmerhorst FM, Rosendaal FR, Vandenbroucke JP. Venous thromboembolism and the pill. The WHO technical report on cardiovascular disease and steroid hormone contraception: state-of-the-art. World Health Organization. Hum Reprod 1998;13:2981-2983.
11. Stuart MJ, Nagel RL. Sickle-cell disease. Lancet 2004;364:1343-1360.
12. Porter JB, Young L, Mackie IJ, et al. Sickle cell disorders and chronic intravascular haemolysis are associated with low plasma heparin cofactor II. Br J Haematol 1993;83:459-465.
13. Kuhl H. Effects of progestogens on haemostasis. Maturitas 1996;24:1-19.
14. Mantha S, Karp R, Raghavan V, et al. Assessing the risk of venous thromboembolic events in women taking progestin-only contraception: a meta-analysis. BMJ 2012;345:e4944.
15. Vasilakis C, Jick H, del Mar Melero-Montes M. Risk of idiopathic venous thromboembolism in users of progestogens alone. Lancet 1999;354:1610-1611.
16. Conard J, Plu-Bureau G, Bahi N, et al. Progestogen-only contraception in women at high risk of venous thromboembolism. Contraception 2004;70:437-441.
17. Hatcher R, Rinehart W, Blackburn R, et al. The Essentials of Contraceptive Technology. Baltimore, MD: Johns Hopkins Bloomberg School of Public Health, Population Information Program, 1997.
18. Hickey M, Fraser IS. The structure of endometrial microvessels. Hum Reprod 2000;15(Suppl. 3):57-66.
19. Hickey M, Krikun G, Kodaman P, et al. Long-term progestin-only contraceptives result in reduced endometrial blood flow and oxidative stress. J Clin Endocrinol Metab 2006;91:3633-3638.
20. Lockwood CJ, Runic R, Wan L, et al. The role of tissue factor in regulating endometrial haemostasis: implications for progestin-only contraception. Hum Reprod 2000;15(Suppl. 3):144-151.
21. Faculty of Sexual & Reproductive Healthcare. UK Medical Eligibility Criteria for Contraceptive Use (UKMEC 2009). 2009. http://www.fsrh.org/pdfs/UKMEC2009.pdf [accessed 20 October 2013].
22. Howard RJ, Lillis C, Tuck SM. Contraceptives, counselling, and pregnancy in women with sickle cell disease. BMJ 1993;306:1735-1737.
23. Stata Corp. Stata Statistical Software: Release 11. College Station, TX: StataCorp LP, 2009.
24. De Ceulaer K, Gruber C, Hayes R, et al. Medroxyprogesterone acetate and homozygous sickle-cell disease. Lancet 1982;2:229-231.
25. de Abood M, de Castillo Z, Guerrero F, et al. Effect of Depo-Provera or Microgynon on the painful crises of sickle cell anemia patients. Contraception 1997;56:313-316.
26. Faculty of Sexual & Reproductive Healthcare Clinical Effectiveness Unit. Progestogen-only Implants. 2014. http://www.fsrh.org/pdfs/CEUGuidanceProgestogenOnlyImplants.pdf [accessed 24 February 2014].